temozolomide and Recrudescence studies

Research Excerpts

Excerpt	Relevance	Reference
"Temozolomide-Topotecan combination results in very encouraging ORR and tumour control in children with heavily pretreated recurrent and refractory neuroblastoma with favourable toxicity profile."	9.19	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. ( Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM, 2014)
"We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies."	9.17	Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. ( Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY, 2013)
"PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)."	9.14	Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010)
"Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)."	9.14	Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010)
"Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide."	9.14	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A, 2009)
"Irinotecan and temozolomide have single-agent activity and schedule-dependent synergy against neuroblastoma."	9.14	Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. ( Crews, KR; Daldrup-Link, HE; Groshen, S; Hawkins, RA; Jackson, HA; Maris, JM; Matthay, KK; Park, JR; Reynolds, CP; Stewart, CF; Villablanca, JG; Wagner, LM, 2009)
"To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine."	9.10	Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S, 2002)
"A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse."	9.09	A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000)
"Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas."	8.86	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010)
"Temozolomide (TMZ) is an alkylating agent previously used in conjunction with doxorubicin (DOX) to treat dogs with relapsed lymphoma."	7.88	Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. ( Baines, SJ; Blackwood, L; Elliott, JW; Treggiari, E, 2018)
"Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients."	7.79	Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. ( Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S, 2013)
"We retrospectively reviewed nine cases of relapsed medulloblastoma treated with bevacizumab, irinotecan, ± temozolomide."	7.79	Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. ( Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY, 2013)
"Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy."	7.78	A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. ( Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012)
" We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide."	7.76	Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010)
"Temozolomide is an easily administered, well-tolerated chemotherapeutic option in advanced or recurrent uterine leiomyosarcomas with a reasonable response rate."	7.76	Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. ( Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC, 2010)
"Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma."	7.73	Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. ( Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P, 2005)
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."	6.76	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor."	6.74	Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009)
"Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization."	6.69	Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999)
"Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms."	5.37	Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011)
"Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4."	5.35	Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008)
"Temozolomide-Topotecan combination results in very encouraging ORR and tumour control in children with heavily pretreated recurrent and refractory neuroblastoma with favourable toxicity profile."	5.19	Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. ( Aerts, I; Amoroso, L; Boubaker, A; Casanova, M; Chastagner, P; Courbon, F; Devos, A; Di Giannatale, A; Dias-Gastellier, N; Ducassoul, S; Geoerger, B; Landman-Parker, J; Le Deley, MC; Malekzadeh, K; Mc Hugh, K; Munzer, C; Riccardi, R; Rubie, H; Verschuur, A; Zwaan, CM, 2014)
"We initiated a prospective multicenter phase II trial using rituximab and temozolomide in immunocompetent patients with progressive or recurrent primary central nervous system lymphoma (PCNSL) based on activity observed in retrospective studies."	5.17	Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. ( Abrey, LE; Deangelis, LM; Drappatz, J; Gilbert, MR; Nayak, L; Omuro, A; Prados, M; Reardon, DA; Wen, PY, 2013)
"Forty-two patients with glioblastoma and 16 patients with anaplastic glioma who had received concurrent radiation and temozolomide and adjuvant temozolomide were enrolled at first relapse."	5.15	Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. ( Aldape, K; Chang, SM; Chen, A; Cloughesy, TF; de Groot, JF; Deangelis, LM; Gilbert, MR; Jackson, EF; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Yao, J; Yung, WK, 2011)
"PURPOSE Concomitant temozolomide (TMZ)/radiotherapy followed by adjuvant TMZ has increased survival in patients with glioblastoma multiforme (GBM)."	5.14	Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. ( Bélanger, K; Easaw, J; Eisenstat, DD; Forsyth, P; Fulton, D; Kavan, P; Kirby, S; Macdonald, DR; Mason, WP; Perry, JR; Pouliot, JF; Shields, C; Thiessen, B, 2010)
"Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG)."	5.14	Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. ( Beall, S; Brada, M; Collins, VP; Erridge, S; Gabe, R; Gattamaneni, R; Hopkins, K; Lee, SM; Levy, D; Rampling, R; Saran, F; Stenning, S; Thompson, LC, 2010)
"Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide."	5.14	Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). ( Amistà, P; Bianchini, C; Blatt, V; Brandes, AA; Ermani, M; Faedi, M; Franceschi, E; Gardiman, M; Labianca, R; Reni, M; Santoro, A; Tosoni, A, 2009)
"Irinotecan and temozolomide have single-agent activity and schedule-dependent synergy against neuroblastoma."	5.14	Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. ( Crews, KR; Daldrup-Link, HE; Groshen, S; Hawkins, RA; Jackson, HA; Maris, JM; Matthay, KK; Park, JR; Reynolds, CP; Stewart, CF; Villablanca, JG; Wagner, LM, 2009)
"To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine."	5.10	Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. ( Amistà, P; Basso, U; Berti, F; Brandes, AA; Ermani, M; Gardiman, M; Iuzzolino, P; Lumachi, F; Monfardini, S; Paris, MK; Turazzi, S, 2002)
"A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse."	5.09	A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. ( Albright, RE; Brada, M; Bruner, J; Fink, K; Fredericks, R; Friedman, H; Glantz, M; Greenberg, H; Hohl, RJ; Levin, VA; Olson, J; Osoba, D; Phillips, P; Prados, MD; Rampling, R; Selker, RG; Shapiro, W; Spence, A; Vick, NA; Yue, N; Yung, WK; Zaknoen, S, 2000)
"Glioblastoma (GBM) has proven to be incurable despite recent progress on its standard of care using temozolomide (TMZ) as the main trunk of initial therapy for newly diagnosed GBM."	4.91	Dose-dense temozolomide: is it still promising? ( Nagane, M, 2015)
"Glioblastoma is a brain tumor with poor prognosis in the therapy of which operation, postoperative temozolomide sensitized radiochemotherapy followed by temozolomide monotherapy offer the best chances."	4.88	[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. ( Bassam, A; Nagy, KA; Pikó, B; Puskásné Szatmári, K; Török, E; Vághy, R; Vargáné Tamás, R, 2012)
"Temozolomide-based chemotherapy represents an incremental improvement in the treatment of patients with high-grade gliomas."	4.86	Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. ( Chamberlain, MC, 2010)
"Temozolomide (TMZ) is an alkylating agent previously used in conjunction with doxorubicin (DOX) to treat dogs with relapsed lymphoma."	3.88	Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. ( Baines, SJ; Blackwood, L; Elliott, JW; Treggiari, E, 2018)
"Radiotherapy with concomitant and adjuvant temozolomide (six cycles) is the standard treatment after surgery in glioblastoma patients."	3.79	Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. ( Baumann, C; Beauchesne, P; Blonski, M; Chauffert, B; Darlix, A; Ghiringhelli, F; Lorgis, V; Pinelli, C; Rech, F; Taillandier, L; Zouaoui, S, 2013)
"Although implementation of temozolomide (TMZ) as a part of primary therapy for glioblastoma multiforme (GBM) has resulted in improved patient survival, the disease is still incurable."	3.79	Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. ( Broholm, H; Christensen, IJ; Grunnet, K; Kosteljanetz, M; Michaelsen, SR; Poulsen, HS; Stockhausen, MT, 2013)
" MRSI and CE abnormalities are now integrated for glioblastoma SIB-IMRT, concomitant with temozolomide, in an ongoing multi-institutional phase-III clinical trial."	3.79	Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. ( Berry, I; Cassol, E; Celsis, P; Cohen-Jonathan, EM; Delannes, M; Filleron, T; Franceries, X; Ken, S; Laprie, A; Lotterie, JA; Lubrano, V; Simon, L; Supper, C; Vieillevigne, L, 2013)
"We retrospectively reviewed nine cases of relapsed medulloblastoma treated with bevacizumab, irinotecan, ± temozolomide."	3.79	Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. ( Aguilera, D; Castellino, RC; Fangusaro, J; Hayes, LL; Kim, S; MacDonald, TJ; Mazewski, C; McNall-Knapp, RY, 2013)
"Treatment of patients with glioblastoma improved dramatically when concomitant and adjuvant temozolomide was added to external radiation therapy."	3.78	A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. ( Bergqvist, M; Bergström, S; Blomquist, E; Ekman, S; Henriksson, R; Johansson, F, 2012)
" We present the case of a 26-year-old male suffering a fatal ICH in the context of treatment of a high grade glioma with temozolomide."	3.76	Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. ( Anderson, WS; Dunn, I; Norden, A; Sure, D, 2010)
"Temozolomide is an easily administered, well-tolerated chemotherapeutic option in advanced or recurrent uterine leiomyosarcomas with a reasonable response rate."	3.76	Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. ( Atkins, KA; Ferriss, JS; Jazaeri, AA; Lachance, JA; Modesitt, SC, 2010)
"Temozolomide (TMZ) is an oral alkylating agent with demonstrated efficacy as therapy for glioblastoma multiforme (GBM) and anaplastic astrocytoma."	3.73	Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. ( Hallinen, T; Kivioja, A; Martikainen, JA; Vihinen, P, 2005)
"Survival at 24 and 30 months after recurrence was 20."	3.30	Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. ( Abram, S; Aiken, RD; Ansstas, G; Ashkan, K; Avigan, DE; Baskin, DS; Battiste, JD; Bosch, ML; Bota, DA; Boynton, AL; Brem, S; Brenner, AJ; Campian, JL; Chaudhary, R; Cobbs, CS; D'Andre, S; Dunbar, EM; Elinzano, H; Etame, AB; Ewend, MG; Fink, KL; Geoffroy, FJ; Giglio, P; Gligich, O; Goldlust, SA; Grewal, J; Heth, JA; Iwamoto, FM; Kesari, S; Khagi, S; Kim, L; Krex, D; Lacroix, M; Lee, IY; Liau, LM; Lillehei, K; Lindhorst, SM; Loudon, WG; Lovick, DS; Lutzky, J; Martinez, NL; Mathieu, D; May, SA; Meisel, HJ; Mikkelsen, T; Moshel, YA; Mulholland, PJ; Nadji-Ohl, M; Nam, JY; New, PZ; Peak, S; Pearlman, ML; Petrecca, K; Piccioni, DE; Pillainayagam, CP; Pluard, TJ; Portnow, J; Prins, RM; Salacz, ME; Sanchin, L; Schulder, M; Sloan, A; Taylor, LP; Thompson, RC; Toms, SA; Tran, DD; Trusheim, JE; Tse, V; Villano, JL; Wagner, SA; Walbert, T; Walter, KA; Wu, JK, 2023)
" There was no clear relationship between vorinostat dosage and drug exposure over the dose range studied."	2.78	A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. ( Ahern, C; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Horton, T; Hummel, TR; Ingle, AM; McGovern, RM; Reid, JM; Wagner, L; Weigel, B, 2013)
"Temozolomide has activity in relapsed SCLC, particularly for brain metastases."	2.77	Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker. ( Azzoli, CG; Chan, TA; Fiore, JJ; Ginsberg, MS; Heguy, A; Holodny, AI; Huberman, K; Kadota, K; Kris, MG; Krug, LM; Pietanza, MC; Riely, GJ; Rizvi, NA; Sima, CS; Sumner, DK; Travis, WD, 2012)
" In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity."	2.76	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"The prognosis for recurrent/progressive Ewing sarcoma (ES) remains poor."	2.74	Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. ( Casey, DA; Chou, AJ; Merchant, MS; Merola, PR; Meyers, PA; Price, AP; Wexler, LH, 2009)
"Ifosfamide treatment might be a feasible approach, but it necessitates hospitalization."	2.69	Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide. ( Bamberg, M; Becker, G; Belka, C; Classen, J; Hoffmann, W; Kortmann, RD; Paulsen, F; Weinmann, M, 1999)
"Glioblastoma multiforme is one of the most common malignant types of tumor arising from the central nervous system known for its devastating intracranial progress and dismal prognosis."	1.62	FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis. ( Malik, D, 2021)
"Tumor recurrence is the main cause of poor prognosis of GBM."	1.51	Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma. ( Li, P; Liu, J; Pan, J; Sun, Z; Tan, N; Zhao, W, 2019)
"Fotemustine (FTM) is a third-generation nitrosourea showing efficacy in gliomas and it has been used with different schedules in adult patients."	1.43	Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. ( Bellu, L; D'Avella, D; Della Puppa, A; Farina, M; Fiduccia, P; Lombardi, G; Pambuku, A; Zagonel, V, 2016)
"Intracranial anaplastic ependymomas are a very rare entity within the group of adult CNS neoplasms."	1.37	Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( Freyschlag, CF; Lohr, F; Schmieder, K; Seiz, M; Thomé, C; Tuettenberg, J, 2011)
"Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4."	1.35	Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. ( Cheung, NK; Kramer, K; Kushner, BH; Laquaglia, MP; Modak, S, 2008)
"At the time of the initial disease recurrence, 13 patients were readministered TMZ."	1.33	Salvage temozolomide for prior temozolomide responders. ( Abrey, LE; Demopoulos, A; Franceschi, E; Lassman, AB; Nolan, C; Omuro, AM, 2005)

Research

Studies (54)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Dose Limiting Toxicity

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.85)	18.2507
2000's	14 (25.93)	29.6817
2010's	35 (64.81)	24.3611
2020's	4 (7.41)	2.80

Authors	Studies
Liau, LM	3
Ashkan, K	3
Brem, S	3
Campian, JL	3
Trusheim, JE	3
Iwamoto, FM	3
Tran, DD	3
Ansstas, G	3
Cobbs, CS	3
Heth, JA	3
Salacz, ME	3
D'Andre, S	3
Aiken, RD	3
Moshel, YA	3
Nam, JY	3
Pillainayagam, CP	3
Wagner, SA	3
Walter, KA	3
Chaudhary, R	3
Goldlust, SA	3
Lee, IY	3
Bota, DA	3
Elinzano, H	3
Grewal, J	3
Lillehei, K	3
Mikkelsen, T	3
Walbert, T	3
Abram, S	3
Brenner, AJ	3
Ewend, MG	3
Khagi, S	3
Lovick, DS	3
Portnow, J	3
Kim, L	3
Loudon, WG	3
Martinez, NL	3
Thompson, RC	3
Avigan, DE	3
Fink, KL	3
Geoffroy, FJ	3
Giglio, P	3
Gligich, O	3
Krex, D	3
Lindhorst, SM	3
Lutzky, J	3
Meisel, HJ	3
Nadji-Ohl, M	3
Sanchin, L	3
Sloan, A	3
Taylor, LP	3
Wu, JK	3
Dunbar, EM	3
Etame, AB	3
Kesari, S	3
Mathieu, D	3
Piccioni, DE	3
Baskin, DS	3
Lacroix, M	3
May, SA	3
New, PZ	3
Pluard, TJ	3
Toms, SA	3
Tse, V	3
Peak, S	3
Villano, JL	3
Battiste, JD	3
Mulholland, PJ	3
Pearlman, ML	3
Petrecca, K	3
Schulder, M	3
Prins, RM	3
Boynton, AL	3
Bosch, ML	3
Beige, A	3
Ghiringhelli, F	4
Lecuelle, J	3
Truntzer, C	3
Truc, G	3
Vincent, J	3
Farah, W	3
Borsotti, F	3
Mazilu, I	3
Ilie, SM	3
Glavatskyi, OY	1
Griazov, AB	1
Chuvashova, OY	1
Kruchok, IV	1
Griazov, AA	1
Khmelnytskyi, HV	1
Shuba, IM	1
Stuley, VA	1
Zemskova, OV	1
Tan, N	1
Liu, J	1
Li, P	1
Sun, Z	1
Pan, J	1
Zhao, W	1
Malik, D	1
Treggiari, E	1
Elliott, JW	1
Baines, SJ	1
Blackwood, L	1
Hummel, TR	1
Wagner, L	1
Ahern, C	1
Fouladi, M	1
Reid, JM	1
McGovern, RM	1
Ames, MM	1
Gilbertson, RJ	1
Horton, T	1
Ingle, AM	1
Weigel, B	1
Blaney, SM	1
Venkatramani, R	1
Malogolowkin, M	1
Davidson, TB	1
May, W	1
Sposto, R	1
Mascarenhas, L	1
Darlix, A	1
Baumann, C	1
Lorgis, V	1
Blonski, M	1
Chauffert, B	1
Zouaoui, S	1
Pinelli, C	1
Rech, F	1
Beauchesne, P	1
Taillandier, L	1
Zustovich, F	1
Landi, L	1
Lombardi, G	2
Porta, C	1
Galli, L	1
Fontana, A	1
Amoroso, D	1
Galli, C	1
Andreuccetti, M	1
Falcone, A	1
Zagonel, V	2
Michaelsen, SR	1
Christensen, IJ	1
Grunnet, K	1
Stockhausen, MT	1
Broholm, H	1
Kosteljanetz, M	1
Poulsen, HS	1
Di Giannatale, A	1
Dias-Gastellier, N	1
Devos, A	1
Mc Hugh, K	1
Boubaker, A	1
Courbon, F	1
Verschuur, A	1
Ducassoul, S	1
Malekzadeh, K	1
Casanova, M	1
Amoroso, L	1
Chastagner, P	1
Zwaan, CM	1
Munzer, C	1
Aerts, I	1
Landman-Parker, J	1
Riccardi, R	1
Le Deley, MC	1
Geoerger, B	1
Rubie, H	1
Nagane, M	1
Cassou-Mounat, T	1
Delwail, V	1
Cayssials, E	1
Terroir, M	1
Puyade, M	1
Bellu, L	1
Pambuku, A	1
Della Puppa, A	1
Fiduccia, P	1
Farina, M	1
D'Avella, D	1
Kushner, BH	1
Laquaglia, MP	1
Kramer, K	1
Modak, S	1
Cheung, NK	1
Brandes, AA	2
Tosoni, A	1
Franceschi, E	2
Blatt, V	1
Santoro, A	1
Faedi, M	1
Amistà, P	2
Gardiman, M	2
Labianca, R	1
Bianchini, C	1
Ermani, M	2
Reni, M	1
Wagner, LM	1
Villablanca, JG	1
Stewart, CF	1
Crews, KR	1
Groshen, S	1
Reynolds, CP	1
Park, JR	1
Maris, JM	1
Hawkins, RA	1
Daldrup-Link, HE	1
Jackson, HA	1
Matthay, KK	1
Annibali, O	1
Nobile, C	1
Greco, R	1
Cellini, F	1
Quattrocchi, CC	1
Tirindelli, MC	1
Petrucci, MT	1
Avvisati, G	1
Seiter, K	1
Katragadda, S	1
Ponce, D	1
Rasul, M	1
Ahmed, N	1
Casey, DA	1
Wexler, LH	1
Merchant, MS	1
Chou, AJ	1
Merola, PR	1
Price, AP	1
Meyers, PA	1
Verhoeff, JJC	1
Lavini, C	1
van Linde, ME	1
Stalpers, LJA	1
Majoie, CBLM	1
Reijneveld, JC	1
van Furth, WR	1
Richel, DJ	1
Ferriss, JS	1
Atkins, KA	1
Lachance, JA	1
Modesitt, SC	1
Jazaeri, AA	1
Wen, PY	3
Perry, JR	1
Bélanger, K	1
Mason, WP	1
Fulton, D	1
Kavan, P	1
Easaw, J	1
Shields, C	1
Kirby, S	1
Macdonald, DR	1
Eisenstat, DD	1
Thiessen, B	1
Forsyth, P	1
Pouliot, JF	1
Sure, D	1
Dunn, I	1
Norden, A	1
Anderson, WS	1
Reardon, DA	2
Vredenburgh, JJ	1
Desjardins, A	1
Peters, K	1
Gururangan, S	1
Sampson, JH	1
Marcello, J	1
Herndon, JE	1
McLendon, RE	1
Janney, D	1
Friedman, AH	1
Bigner, DD	1
Friedman, HS	1
Brada, M	2
Stenning, S	1
Gabe, R	1
Thompson, LC	1
Levy, D	1
Rampling, R	2
Erridge, S	1
Saran, F	1
Gattamaneni, R	1
Hopkins, K	1
Beall, S	1
Collins, VP	1
Lee, SM	1
Chamberlain, MC	1
Terasaki, M	1
Shibui, S	1
Narita, Y	1
Fujimaki, T	1
Aoki, T	1
Kajiwara, K	1
Sawamura, Y	1
Kurisu, K	1
Mineta, T	1
Yamada, A	1
Itoh, K	1
Chinot, OL	1
de La Motte Rouge, T	1
Moore, N	1
Zeaiter, A	1
Das, A	1
Phillips, H	1
Modrusan, Z	1
Cloughesy, T	1
Freyschlag, CF	1
Tuettenberg, J	1
Lohr, F	1
Thomé, C	1
Schmieder, K	1
Seiz, M	1
de Groot, JF	1
Lamborn, KR	1
Chang, SM	1
Gilbert, MR	2
Cloughesy, TF	1
Aldape, K	1
Yao, J	1
Jackson, EF	1
Lieberman, F	1
Robins, HI	1
Mehta, MP	1
Lassman, AB	2
Deangelis, LM	2
Yung, WK	2
Chen, A	1
Prados, MD	2
Schäfer, N	1
Tichy, J	1
Thanendrarajan, S	1
Kim, Y	1
Stuplich, M	1
Mack, F	1
Rieger, J	1
Simon, M	1
Scheffler, B	1
Boström, J	1
Steinbach, JP	1
Herrlinger, U	1
Glas, M	1
Narayana, A	1
Gruber, D	1
Kunnakkat, S	1
Golfinos, JG	1
Parker, E	1
Raza, S	1
Zagzag, D	1
Eagan, P	1
Gruber, ML	1
Pietanza, MC	1
Kadota, K	1
Huberman, K	1
Sima, CS	1
Fiore, JJ	1
Sumner, DK	1
Travis, WD	1
Heguy, A	1
Ginsberg, MS	1
Holodny, AI	1
Chan, TA	1
Rizvi, NA	1
Azzoli, CG	1
Riely, GJ	1
Kris, MG	1
Krug, LM	1
Montano, N	1
Cenci, T	1
Martini, M	1
D'Alessandris, QG	1
Pelacchi, F	1
Ricci-Vitiani, L	1
Maira, G	1
De Maria, R	1
Larocca, LM	1
Pallini, R	1
Nayak, L	1
Abrey, LE	2
Drappatz, J	1
Prados, M	1
Omuro, A	1
Zhang, N	1
Wu, X	1
Yang, L	1
Xiao, F	1
Zhang, H	1
Zhou, A	1
Huang, Z	1
Huang, S	2
Osmani, AH	1
Masood, N	1
Johansson, F	1
Ekman, S	1
Blomquist, E	1
Henriksson, R	1
Bergström, S	1
Bergqvist, M	1
Pikó, B	1
Bassam, A	1
Nagy, KA	1
Török, E	1
Vághy, R	1
Vargáné Tamás, R	1
Puskásné Szatmári, K	1
Okada, M	1
Miyake, K	1
Shinomiya, A	1
Kawai, N	1
Tamiya, T	1
Ken, S	1
Vieillevigne, L	1
Franceries, X	1
Simon, L	1
Supper, C	1
Lotterie, JA	1
Filleron, T	1
Lubrano, V	1
Berry, I	1
Cassol, E	1
Delannes, M	1
Celsis, P	1
Cohen-Jonathan, EM	1
Laprie, A	1
Aguilera, D	1
Mazewski, C	1
Fangusaro, J	1
MacDonald, TJ	1
McNall-Knapp, RY	1
Hayes, LL	1
Kim, S	1
Castellino, RC	1
Basso, U	1
Paris, MK	1
Lumachi, F	1
Berti, F	1
Iuzzolino, P	1
Turazzi, S	1
Monfardini, S	1
Hongeng, S	1
Visudtibhan, A	1
Dhanachai, M	1
Laothamatus, J	1
Chiamchanya, S	1
Martikainen, JA	1
Kivioja, A	1
Hallinen, T	1
Vihinen, P	1
Omuro, AM	1
Demopoulos, A	1
Nolan, C	1
Mutter, N	1
Stupp, R	1
Paulsen, F	1
Hoffmann, W	1
Becker, G	1
Belka, C	1
Weinmann, M	1
Classen, J	1
Kortmann, RD	1
Bamberg, M	1
Janinis, J	1
Efstathiou, E	1
Panopoulos, C	1
Samantas, E	1
Aravantinos, G	1
Christodoulou, C	1
Skarlos, D	1
Albright, RE	1
Olson, J	1
Fredericks, R	1
Fink, K	1
Spence, A	1
Hohl, RJ	1
Shapiro, W	1
Glantz, M	1
Greenberg, H	1
Selker, RG	1
Vick, NA	1
Friedman, H	1
Phillips, P	1
Bruner, J	1
Yue, N	1
Osoba, D	1
Zaknoen, S	1
Levin, VA	1
Dinnes, J	1
Cave, C	1
Major, K	1
Milne, R	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)[NCT00045968]	Phase 3	348 participants (Anticipated)	Interventional	2006-12-31	Active, not recruiting
A Phase I Study of SAHA and Temozolomide in Children With Relapsed or Refractory Primary Brain or Spinal Cord Tumors[NCT01076530]	Phase 1	27 participants (Actual)	Interventional	2010-02-28	Completed
A Phase I Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin[NCT00993044]	Phase 1	13 participants (Actual)	Interventional	2009-09-30	Completed
Glioblastoma Multiforme Patients in Clinical Trials: An Examination of Their Clinical Trial Experiences[NCT05958485]		500 participants (Anticipated)	Observational	2024-08-31	Not yet recruiting
A Phase I Study Of Oral Irinotecan, Temozolomide, Cefixime In Children With Recurrent/Resistant High-Risk Neuroblastoma[NCT00093353]	Phase 1	30 participants (Anticipated)	Interventional	2004-05-31	Completed
Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients[NCT03542097]		82 participants (Actual)	Observational	2014-04-15	Completed
The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial[NCT01847235]	Phase 2	23 participants (Actual)	Interventional	2013-05-31	Completed
The Temozolomide RESCUE Study: A Phase II Trial of Continuous (28/28) Dose-intense Temozolomide (CDIT) Chemotherapy After Progression on Conventional 5/28 Day Temozolomide in Patients With Recurrent Malignant Glioma[NCT00392171]	Phase 2	120 participants (Actual)	Interventional	2006-06-09	Completed
Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients[NCT02227576]	Phase 2	20 participants (Actual)	Interventional	2014-07-10	Terminated (stopped due to Study halted for efficacy following the results of the interim analysis provided for in the protocol on 20 patients.)
Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493]	Phase 2	32 participants (Actual)	Interventional	2007-09-30	Completed
A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV[NCT00052455]	Phase 3	500 participants (Anticipated)	Interventional	2002-10-31	Completed
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas[NCT00369590]	Phase 2	58 participants (Actual)	Interventional	2006-08-31	Completed
A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma[NCT00248534]	Phase 2	16 participants (Actual)	Interventional	2005-09-30	Terminated (stopped due to slow accrual/lack of resources/low priority due to combining 2 consortia)
Role of Repeat Resection in Recurrent Glioblastoma (4rGBM) Trial: a Randomized Care Trial for Patients With Recurrent GBM[NCT04838782]		250 participants (Anticipated)	Interventional	2021-08-26	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of participants with dose limiting toxicity events (NCT00993044)
Timeframe: 2 years

Percentage of Participants Surviving at Six Months of Treatment Without Evidence of Disease Progression.

Intervention	participants (Number)
Single Arm	2

Progression-free survival as determined by Kaplan-Meier method. (NCT00392171)
Timeframe: 6 months

6 Month Progression Free Survival (PFS)

Intervention	Percentage of Participants (Number)
	Anaplastic Glioma (n=28)	Early Glioblastoma Multiforme (GBM) (n=33)	Extended Glioblastoma Multiforme (GBM) (n=27)	Rechallenge Glioblastoma Multiforme (GBM) (n=28)
Temozolomide	35.7	27.3	7.4	35.7

Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months

Pharmacokinetics: AUC-24

Intervention	percentage of patients (Number)
Sorafenib + Temozolomide	9.4

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Pharmacokinetics: C-max

Intervention	ug*H/L (Geometric Mean)
EIAEDs-Day 1	45309.7
EIAEDs-Day 28	47148.2
Non-EIAEDs-Day 1	45238.7
Non-EIAEDs-Day 28	128820.8

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Pharmacokinetics: T-max

Intervention	ug/L (Geometric Mean)
EIAEDs-Day 1	3397.3
EIAEDs-Day 28	3813.9
Non-EIAEDs-Day 1	3155.1
Non-EIAEDs-Day 28	8118.8

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Safety and Toxicity of Combination

Intervention	hours (Median)
EIAEDs-Day 1	8.2
EIAEDs-Day 28	2.1
Non-EIAEDs-Day 1	24.0
Non-EIAEDs-Day 28	4.2

Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months

Overall Survival

Intervention	participants (Number)
Sorafenib + Temozolomide	19

all patients alive as of the last contact were censored for survival on the basis of that contact date (NCT00369590)
Timeframe: 3 years

Progression Free Survival (PFS) Rate for Subjects With Radiographic Response

Intervention	weeks (Median)
Arm I - Anaplastic Glioma	55
Arm 2 - Glioblastoma	39

"pts with confirmed radiographic response and their rate of progression (PFS).~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: up to 3 years

Progression-free Survival (PFS) at 6 Months

Intervention	weeks (Median)
Arm I - Anaplastic Glioma	45
Arm 2 - Glioblastoma	23

"This design yields 85% power to detect a true 30% 6-month PFS rate, while maintaining .91 probability of rejecting for a true 15% 6-month PFS rate.~pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression.~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: 6 months

Safety Profile - Events That Discontinued Treatment

Intervention	percentage of participants (Number)
Arm I - Anaplastic Glioma	25
Arm 2 - Glioblastoma	7.7

number of patients who experienced toxicity that led to being taken off treatment (NCT00369590)
Timeframe: Approximately 1 year (start of treatment - end of treatment)

Safety Profile - Toxicities

Intervention	participants (Number)
Arm I - Anaplastic Glioma	8
Arm 2 - Glioblastoma	6

number of cycles patient was able to have before developing a toxicity that required removing the patient from treatment. Treatment: Aflibercept 4mg/kg intravenously on day 1 of every 14-day cycle - 2 week cycle. (NCT00369590)
Timeframe: Start to End of treatment 39 cycles or 1yr 7.5months (78 weeks)

Response Rate Associated With VEGF Trap Therapy Defined as Proportions of Patients Experiencing Complete or Partial Response

Intervention	cycles (Median)
Arm I - Anaplastic Glioma	5
Arm 2 - Glioblastoma	3.5

"pts had MRIs at screening and at the 3rd and 5th cycles then every 8 weeks until progression. All responders were centrally reviewed for confirmation~Response determined by modified MacDonald Criteria Complete Response (CR): Complete disappearance of all measurable and evaluable disease, no new lesions. no steroids Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable lesions. no new lesions. steroid dose no > than maximum dose used in first 8 weeks of treatment.~Stable: Does not qualify for CR, PR, or progression steroid dose no > than maximum dose used in first 8 weeks of treatment.~Progression: 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no increase) Clear clinical worsening." (NCT00369590)
Timeframe: Up to 2 years

1 Year Overall Survival Rate

6-month Progression-free Survival

Intervention	participants (Number)
	Complete Response	Partial Response
Arm 2 - Glioblastoma	0	7
Arm I - Anaplastic Glioma	1	6

Intervention	percentage of participants (Number)
IV Rituximab	71

"Scan at 6 months~Complete response: Complete disappearance of all tumor on MRI scan, off all glucocorticoids with stable or improving neurological exam minimum of 4 wks~Partial response: Greater than or equal 50% reduction in tumor size on MRI, on sable or decreasing glucocorticoids with stable or improving neurological exam for a minimum of 4 wks.~Progressive disease: Progressive neurological abnormalities not explained by other causes or greater than 25% increase in size of tumor or if new lesion.~Stable disease: Clinical status and MRI does not qualify for complete response, partial response or progression" (NCT00248534)
Timeframe: 6 months

Number of Participants Alive at 3 Years

Intervention	percentage of participants (Number)
IV Rituximab	13

The intent was to measure Median Overall Survival at 3 years, however only one participant was analyzable at this time point. Therefore, the number of participants who survived is reported instead. (NCT00248534)
Timeframe: 3 years

Percentage of Participants With Objective Response

Intervention	Participants (Count of Participants)
IV Rituximab	1

Objective response rate of the combination of Rituximab and TMZ (NCT00248534)
Timeframe: 2 months

Article	Year
Dose-dense temozolomide: is it still promising? Neurologia medico-chirurgica, 2015, Volume: 55, Issue:1 Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dacarbazine; Disease Progression; Dose-	2015
Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert review of neurotherapeutics, 2010, Volume: 10, Issue:10 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic	2010
[Use of angioneogenesis inhibitor monoclonal antibody following standard therapy in recurrent or progressive glioblastoma multiforme]. Magyar onkologia, 2012, Volume: 56, Issue:3 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antin	2012
Temozolomide: a milestone in neuro-oncology and beyond? Expert review of anticancer therapy, 2006, Volume: 6, Issue:8 Topics: Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Clinical Trials, Phase II as	2006
The effectiveness and cost-effectiveness of temozolomide for the treatment of recurrent malignant glioma: a rapid and systematic review. Health technology assessment (Winchester, England), 2001, Volume: 5, Issue:13 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Cost-Benefit Analysis; Dacarbazine; Evidence-Bas	2001

Article	Year
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study. Anticancer research, 2022, Volume: 42, Issue:12 Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv	2022
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study. Anticancer research, 2022, Volume: 42, Issue:12 Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv	2022
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study. Anticancer research, 2022, Volume: 42, Issue:12 Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv	2022
Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study. Anticancer research, 2022, Volume: 42, Issue:12 Topics: Bevacizumab; Chronic Disease; Cytotoxins; Glioblastoma; Humans; Irinotecan; Recurrence; Retrospectiv	2022
RADIOSURGICAL TREATMENT OF RECURRENT GLIOBLASTOMA AND PROGNOSTIC FACTORS AFFECTING TREATMENT OUTCOMES. Experimental oncology, 2022, Volume: 44, Issue:4 Topics: Adult; Brain Neoplasms; Glioblastoma; Humans; Neoplasm Recurrence, Local; Prognosis; Radiosurgery; R	2022
Reactive oxygen species metabolism-based prediction model and drug for patients with recurrent glioblastoma. Aging, 2019, 12-04, Volume: 11, Issue:23 Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antioxidants; Cell Line, Tumor; Cell	2019
FDG PET/CT in Recurrent Glioblastoma Multiforme With Leptomeningeal and Diffuse Spinal Cord Metastasis. Clinical nuclear medicine, 2021, Feb-01, Volume: 46, Issue:2 Topics: Adult; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioblastoma; Humans; Meningeal Neoplasms; P	2021
Temozolomide alone or in combination with doxorubicin as a rescue agent in 37 cases of canine multicentric lymphoma. Veterinary and comparative oncology, 2018, Volume: 16, Issue:2 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che	2018
Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer research, 2013, Volume: 33, Issue:8 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms	2013
Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC cancer, 2013, Sep-03, Volume: 13 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biom	2013
Use of temozolomide instead of cyclophosphamide in diffuse large B-cell lymphoma. Leukemia & lymphoma, 2016, Volume: 57, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Dacarbazine; Drug Hypersen	2016
Clinical outcome of an alternative fotemustine schedule in elderly patients with recurrent glioblastoma: a mono-institutional retrospective study. Journal of neuro-oncology, 2016, Volume: 128, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; DNA Methylation; DNA M	2016
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide. Pediatric blood & cancer, 2008, Volume: 51, Issue:4 Topics: Adolescent; Adult; Cell Transformation, Neoplastic; Child; Combined Modality Therapy; Dacarbazine; F	2008
The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse. International journal of hematology, 2009, Volume: 89, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality	2009
Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:8 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize	2010
Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:1 Topics: Adult; Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; Biomarkers, Tumor; Dacarbazin	2010
Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Apr-20, Volume: 28, Issue:12 Topics: Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Disease Pro	2010
Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide. Clinical neurology and neurosurgery, 2010, Volume: 112, Issue:8 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cerebral Hemorrhage; Dacarbazine; Dose-Re	2010
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. Anticancer research, 2011, Volume: 31, Issue:3 Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Disease Progression; Ependymoma; Female;	2011
Ifosfamide, carboplatin and etoposide in recurrent malignant glioma. Oncology, 2011, Volume: 80, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplat	2011
Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; ErbB Receptors; Fema	2011
FoxM1 inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA-repair gene Rad51. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-01, Volume: 18, Issue:21 Topics: Antineoplastic Agents, Alkylating; Binding Sites; Cell Line, Tumor; Dacarbazine; DNA Repair; Drug Re	2012
Temozolomide for relapsed primary CNS lymphoma. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2012, Volume: 22, Issue:9 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Ne	2012
A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai	2012
Relapse of herpes encephalitis induced by temozolomide-based chemoradiation in a patient with malignant glioma. Journal of neurosurgery, 2013, Volume: 118, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Encephali	2013
Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. Radiation oncology (London, England), 2013, Jan-02, Volume: 8 Topics: Brain Neoplasms; Contrast Media; Dacarbazine; Glioblastoma; Humans; Image Processing, Computer-Assis	2013
Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013, Volume: 29, Issue:4 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac	2013
Treatment of leptomeningeal relapse of medulloblastoma with temozolomide. Journal of pediatric hematology/oncology, 2002, Volume: 24, Issue:7 Topics: Brain; Child; Dacarbazine; Humans; Magnetic Resonance Imaging; Male; Medulloblastoma; Recurrence; Te	2002
Economic evaluation of temozolomide in the treatment of recurrent glioblastoma multiforme. PharmacoEconomics, 2005, Volume: 23, Issue:8 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;	2005
Salvage temozolomide for prior temozolomide responders. Cancer, 2005, Dec-01, Volume: 104, Issue:11 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Dacarbazine; Female; G	2005

temozolomide and Recrudescence